PsilodexMedication × psilocybin
Your list , 0 items
General prescriptions
Brand names
Zarontin
Reviewed 2026-10-04

Ethosuximide

A succinimide anticonvulsant, FDA-approved for absence (petit mal) epilepsy.

psilodex.org/m/ethosuximide · data v2026.10.05

Clinical contraindication
None listed
No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence
No psilocybin data
Half-life
Not stated in label or references
Named in state rules?
Not namedColorado Condition rules (3)
Not namedOregon
PendingNew Mexico
Cite asPsilodex, “Ethosuximide”, v2026.10.05. psilodex.org/m/ethosuximide

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for
  • Absence (petit mal) seizures
Sources [1]

01 Interaction with psilocybin

ND

Not studied with psilocybin; no linking mechanism is described. Stopping it suddenly after regular use can cause seizures.

Detail Not studied with psilocybin, and no mechanism linking them has been described. Separately, its label lists drowsiness, dizziness and rare psychiatric reactions, including paranoid psychosis. It also carries the suicidality warning given for all antiepileptic drugs. Used alone in mixed epilepsy, it may increase grand mal seizures. Abrupt withdrawal may bring on absence status (prolonged absence seizures). Sources [1]

Human data with psilocybin
No psilocybin data; based on its label
Evidence types on this record
No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

4 listed · counted on reports
Sedating or CNS depressant
Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]
Withdrawal or rebound if stopped abruptly
Stopping suddenly can cause withdrawal or a rebound of symptoms. Sources [1]
Psychiatric reactions
The label or source warns of psychiatric effects such as psychosis, mania, hallucinations, suicidal thoughts or severe mood or behavior changes. Psilocybin can also bring up strong emotions, so these warnings are relevant to screening. Sources [1]
Lowers seizure threshold or carries seizure risk
Makes a seizure more likely, or has been linked to seizures. Sources [1]

03 State rules

Plain-language summary · official text governs
CO4 CCR 755-1
Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04
OROAR 333-333
Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04
NM7.35.3 NMAC (proposed)
Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

  • Seizure disorder (usual indication)
    • CO 2.5(A)(2) · Clinical Facilitator licensees
    • CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
    • CO 6.16(F)(1) · All licensees

05 Sources

1
  1. ZARONTIN (ethosuximide) capsule · FDA label (DailyMed) — revised 2026-05 | Psychiatric reactions: WARNINGS - Suicidal Behavior and Ideation "Antiepileptic drugs (AEDs), including Zarontin, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication." | Psychiatric reactions: ADVERSE REACTIONS - Psychiatric "There have been rare reports of paranoid psychosis, increased libido, and increased state of depression with overt suicidal intentions." | Lowers seizure threshold or carries seizure risk: PRECAUTIONS - General "Ethosuximide, when used alone in mixed types of epilepsy, may increase the frequency of grand mal seizures in some patients." | Withdrawal or rebound if stopped abruptly: PRECAUTIONS - General "Abrupt withdrawal of anticonvulsant medication may precipitate absence (petit mal) status." | Sedating or CNS depressant: ADVERSE REACTIONS - Nervous System "Neurologic and sensory reactions reported during therapy with ethosuximide have included drowsiness, headache, dizziness, euphoria, hiccups, irritability, hyperactivity, lethargy, fatigue, and ataxia."

Record history

  • v2026.10.02First published.
  • 2026-10-04Last reviewed against its sources.

Report an error in this record →

Before you startTerms 2026-10-01

What Psilodex is, and isn't.

  1. 01Psilodex summarizes published evidence and public state rules. It does not decide whether you can safely use psilocybin or take part in services, and it is not medical advice.
  2. 02Psilodex presents information only. Do not stop or change a medication without talking with the prescriber. Bring the report to them.
  3. 03Your searches and list stay in this browser and are not sent to us. Opening a medication's page is an ordinary web request, so our hosting providers see which page was opened. What we can and can't see.

In an emergency, call 911. For a mental health crisis, call or text 988. Full terms and privacy.